Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
To the Editor: we have read with considerable interest the paper by Cohen et al 1 estimating the cost-effectiveness of the Mitraclip system in patients with secondary mitral regurgitation (SMR).
Like other published works that adopted different healthcare perspectives, including the one by Baron et al,2 the cost-effectiveness analysis conducted by Cohen et al 1 was based on 2-year data from the Coapt randomised controlled trial (RCT).3
Generating lifetime estimates of survival gain (1.57 years here) from the 2-year data of Coapt requires extensive extrapolation of about 13 years beyond observed data and >95% of benefit reported in the percutaneous repair (PR) arm accrues in the extrapolation phase rather than the observation phase.
The observed source data used for extrapolation can therefore exert a profound influence on estimation of gained benefit from PR.
We were …
Contributors MC and XA drafted the first version of the letter.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests XA is a member of the steering committee of the Mitra-Fr Study, and reports consultancy work undertaken for WL Gore (no personal fees received).
Provenance and peer review Commissioned; internally peer reviewed.
- Valvular heart disease